For Immediate Release
Chicago, IL – March 4, 2010 – Zacks.com announces the latest Industry Outlook. Today, Zacks Equity Research discusses the Health Care Industry, including WellPoint Inc. (WLP), Health Net Inc. (HNT), BioScrip, Inc. (BIOS) and ZOLL Medical Corporation (ZOLL).
A synopsis of today’s Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/31224/Health+Care+Outlook+%26amp%3B+Stock+Review.
Health Care Outlook & Stock Review
President Obama has made a last-ditch effort to revive the stalled U.S. healthcare overhaul with a plan to make insurance more affordable and to bolster government authority to regulate premium hikes. The plan, which aims to break an impasse in the U.S. Congress, intends to provide coverage to millions of uninsured Americans and set up federal monitoring of private insurers’ rate increases. The President’s proposal comes following months of debate on reform in the Senate and House of Representatives over their respective legislation.
As per the plan, health insurers would have to spend at least 80% of their premiums on medical care, a move that could result in penalties for 16% of health insurers. Furthermore, the proposed plan intends to penalize health insurers who spend more than 20% of premiums on operational costs, such as salaries and marketing.
Exorbitant rate hikes and profit margins became the subject of public debate after WellPoint Inc. (WLP) issued letters to the policyholders of its subsidiary Anthem Blue Cross in California, warning them of steep rate hikes.
Recently, the U.S. House of Representatives voted to strip health insurance companies of a 65-year-old antitrust exemption. The 406 to 19 vote aims to repeal an antitrust exemption that has meant that states take the lead in enforcing antitrust law for health insurers.
We are positive on Health Net Inc. (HNT) on which we have an Outperform rating. While we remain concerned about the decline in membership, we believe a gradual improvement of the US economy should improve its membership status. Moreover, a strong balance sheet should enable it to tackle the current scenario.
Health technology holds the promise of improved operating efficiencies for many parts of the healthcare industry, hospitals included. However, in the short term those that stand to benefit the most from the stimulus are companies whose business models are based on information technology platforms.
One such company is BioScrip, Inc. (BIOS) on which we are positive despite its neutral rating. BioScrip is a specialty pharmacy services provider and pharmacy benefit manager. The company operates two interrelated business segments, namely: Specialty Services, which consists of specialty pharmacy distribution and clinical management services; and Traditional Pharmacy Services (previously referred to as PBM Services), which consists of pharmacy benefit management and traditional mail services.
The company’s diversified product mix across several key disease areas including immunology, multiple sclerosis and oncology should drive growth. The oral oncology business continues to show robust growth and should remain a strong part of the company’s business. We are pleased to see that the company is working on expanding its national reach and local presence and is adding infusion capacity in markets which have a large number of members.
We believe BioScrip is well-positioned to benefit from future healthcare reform initiatives like broader insurance coverage, the approval of a pathway for bio-similars and incentives supporting the utilization of information technology systems. The implementation of these initiatives is in line with the company’s strategy and should bode well for its future.
Another company on which we are positive — despite its current Neutral recommendation — is ZOLL Medical Corporation (ZOLL). We are pleased with the company’s wide range of products and significant international presence. The company has made multiple acquisitions in the past, which have aided growth and is looking out for more such opportunities.
The company is a leading player in the global market for external defibrillators, which is worth over $1 billion annually. ZOLL Medical has innovated a wide range of product features that have become the standard of care in the external defibrillator industry. The company is expanding its offerings to sustain growth.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5510.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5511.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
